2-(2-Methyl-4-methoxyphenyl)-5-{[(3R,4S)-4-ethoxy-1-(1,3-thiazol-2-yl)pyrrolidin-3-yl]amino}-6-ethyl-3-methylpyrimidin-4(3H)-one | 590382-66-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-Methyl-4-methoxyphenyl)-5-{[(3R,4S)-4-ethoxy-1-(1,3-thiazol-2-yl)pyrrolidin-3-yl]amino}-6-ethyl-3-methylpyrimidin-4(3H)-one
• 英文别名: 5-[[(3R,4S)-4-ethoxy-1-(1,3-thiazol-2-yl)pyrrolidin-3-yl]amino]-6-ethyl-2-(4-methoxy-2-methylphenyl)-3-methylpyrimidin-4-one
• CAS: 590382-66-4
• 化学式: C₂₄H₃₁N₅O₃S
• 分子量: 469.608
• InChiKey: LANMSPMRFWXXMH-UXHICEINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Substituted pyrimidinones and pyrimidinthiones
  申请人：——

  公开号：US20030195222A1

  公开（公告）日：2003-10-16

  This invention relates to substituted pyrimidinone and pyrimidithione derivatives that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.

  本发明涉及取代的嘧啶酮和嘧啶硫酮衍生物，它们能与 CRF1 受体（包括人类 CRF1 受体）高亲和力结合。本发明还涉及使用本发明化合物治疗紊乱或病症的方法，通过拮抗 CRF 受体可影响或促进紊乱或病症的治疗，如中枢神经系统紊乱或疾病，特别是焦虑症、抑郁症和压力相关紊乱。
• SUBSTITUTED PYRIMIDINONES AND PYRIMIDINTHIONES
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1476165A1

  公开（公告）日：2004-11-17
• [EN] SUBSTITUTED PYRIMIDINONES AND PYRIMIDINTHIONES<br/>[FR] PYRIMIDINONES ET PYRIMIDINTHIONES SUBSTITUES
  申请人：UPJOHN CO

  公开号：WO2003072107A1

  公开（公告）日：2003-09-04

  This invention relates to substituted pyrimidinone and pyrimidithione derivatives that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.